+

WO2009062059A3 - Purinones et 1h-imidazopyridinones isomères comme inhibiteurs de pkc-thêta - Google Patents

Purinones et 1h-imidazopyridinones isomères comme inhibiteurs de pkc-thêta Download PDF

Info

Publication number
WO2009062059A3
WO2009062059A3 PCT/US2008/082832 US2008082832W WO2009062059A3 WO 2009062059 A3 WO2009062059 A3 WO 2009062059A3 US 2008082832 W US2008082832 W US 2008082832W WO 2009062059 A3 WO2009062059 A3 WO 2009062059A3
Authority
WO
WIPO (PCT)
Prior art keywords
imidazopyridinones
purinones
pkc
isomeric
theta inhibitors
Prior art date
Application number
PCT/US2008/082832
Other languages
English (en)
Other versions
WO2009062059A2 (fr
Inventor
Andrew Roughton
Yajing Rong
Koc-Kan Ho
Michael Ohlmeyer
David Diller
Ray Jui-Hsiang Chan
Gaifa Lai
Original Assignee
Pharmacopeia, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacopeia, Llc filed Critical Pharmacopeia, Llc
Publication of WO2009062059A2 publication Critical patent/WO2009062059A2/fr
Publication of WO2009062059A3 publication Critical patent/WO2009062059A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention porte sur un genre chimique de purinones et de 1H-imidazopyridinones, qui sont utiles comme inhibiteurs de PKC, et sur leurs procédés d'utilisation. Le genre est représenté par la Formule (I).
PCT/US2008/082832 2007-11-08 2008-11-07 Purinones et 1h-imidazopyridinones isomères comme inhibiteurs de pkc-thêta WO2009062059A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98645007P 2007-11-08 2007-11-08
US60/986,450 2007-11-08

Publications (2)

Publication Number Publication Date
WO2009062059A2 WO2009062059A2 (fr) 2009-05-14
WO2009062059A3 true WO2009062059A3 (fr) 2009-11-12

Family

ID=40350198

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/082832 WO2009062059A2 (fr) 2007-11-08 2008-11-07 Purinones et 1h-imidazopyridinones isomères comme inhibiteurs de pkc-thêta

Country Status (1)

Country Link
WO (1) WO2009062059A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7919490B2 (en) 2006-10-04 2011-04-05 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7915268B2 (en) 2006-10-04 2011-03-29 Wyeth Llc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
JPWO2008114819A1 (ja) 2007-03-20 2010-07-08 大日本住友製薬株式会社 新規アデニン化合物
KR20100125245A (ko) 2008-01-17 2010-11-30 다이닛본 스미토모 세이야꾸 가부시끼가이샤 아데닌 화합물의 제조 방법
PA8851101A1 (es) 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol
PT2491035T (pt) * 2009-10-22 2017-10-30 Gilead Sciences Inc Derivados de purina ou deazapurina úteis para o tratamento de (entre outros) infeções virais
US8895570B2 (en) 2010-12-17 2014-11-25 Astrazeneca Ab Purine derivatives
EP3046560B1 (fr) * 2013-09-18 2021-01-06 EpiAxis Therapeutics Pty Ltd Modulation de cellules souches
GB201321737D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
EP3365340B1 (fr) 2015-10-19 2022-08-10 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
HUE060680T2 (hu) 2015-11-19 2023-04-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
MX2021001186A (es) 2015-11-20 2022-10-11 Forma Therapeutics Inc Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
PL3394033T3 (pl) 2015-12-22 2021-05-31 Incyte Corporation Związki heterocykliczne jako immunomodulatory
MA44860A (fr) 2016-05-06 2019-03-13 Incyte Holdings Corp Composés hétérocycliques utilisés comme immunomodulateurs
TW201808902A (zh) 2016-05-26 2018-03-16 美商英塞特公司 作為免疫調節劑之雜環化合物
HUE060256T2 (hu) 2016-06-20 2023-02-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
WO2018013789A1 (fr) 2016-07-14 2018-01-18 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP4223369A1 (fr) 2016-12-22 2023-08-09 Incyte Corporation Composés immunomodulateurs et procédés d'utilisation
MA47120A (fr) 2016-12-22 2021-04-28 Incyte Corp Dérivés pyridine utilisés en tant qu'immunomodulateurs
MY197635A (en) 2016-12-22 2023-06-29 Incyte Corp Benzooxazole derivatives as immunomodulators
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
FI4212529T3 (fi) 2018-03-30 2025-04-23 Incyte Corp Heterosyklisiä yhdisteitä immunomodulaattoreina
SG11202011165TA (en) 2018-05-11 2020-12-30 Incyte Corp Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
AR119624A1 (es) 2019-08-09 2021-12-29 Incyte Corp Sales de un inhibidor de pd-1 / pd-l1
EP4037773A1 (fr) 2019-09-30 2022-08-10 Incyte Corporation Composés pyrido[3,2-d]pyrimidine en tant qu'immunomodulateurs
CR20220237A (es) 2019-11-11 2022-08-05 Incyte Corp Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
TWI807228B (zh) * 2019-11-25 2023-07-01 大陸商南京明德新藥研發有限公司 作為dna-pk抑制劑的嘧啶并吡咯類化合物
CR20230230A (es) 2020-11-06 2023-07-27 Incyte Corp Proceso para hacer un inhibidor de pd-1/pdl1 y sales y formas cristalinas del mismo
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
WO2022099075A1 (fr) 2020-11-06 2022-05-12 Incyte Corporation Forme cristalline d'un inhibiteur pd-1/pd-l1
WO2023107705A1 (fr) 2021-12-10 2023-06-15 Incyte Corporation Amines bicycliques utilisées comme inhibiteurs de cdk12

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
WO2008051494A1 (fr) * 2006-10-19 2008-05-02 Signal Pharmaceuticals, Llc Composés hétéroaryle, compositions contenant ces composés et procédés d'utilisation de ces composés en tant qu'inhibiteurs de protéines kinases
WO2008143674A1 (fr) * 2007-05-23 2008-11-27 Pharmacopeia, Inc. Purinones et 1h-imidazopyridinones en tant qu'inhibiteurs de pkc-thêta

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
WO2008051494A1 (fr) * 2006-10-19 2008-05-02 Signal Pharmaceuticals, Llc Composés hétéroaryle, compositions contenant ces composés et procédés d'utilisation de ces composés en tant qu'inhibiteurs de protéines kinases
WO2008143674A1 (fr) * 2007-05-23 2008-11-27 Pharmacopeia, Inc. Purinones et 1h-imidazopyridinones en tant qu'inhibiteurs de pkc-thêta

Also Published As

Publication number Publication date
WO2009062059A2 (fr) 2009-05-14

Similar Documents

Publication Publication Date Title
WO2009062059A3 (fr) Purinones et 1h-imidazopyridinones isomères comme inhibiteurs de pkc-thêta
MX2009012612A (es) Purinonas e inhibidores 1h-imidazopiridinonas como pkc-theta.
WO2008051826A3 (fr) Purines en tant qu'inhibiteurs de pkc-theta
WO2009156462A3 (fr) Composés organiques
WO2008025856A3 (fr) Protéines modifiées
TN2010000148A1 (en) Amide compound
WO2010011407A3 (fr) Procédés de génération de substrats souples modelés et leurs utilisations
WO2007109080A3 (fr) Inhibiteurs de protéase de l'hépatite c deutérés
WO2006116622A3 (fr) Nouveaux procedes et dispositifs d'evaluation de substances toxiques
WO2008005375A3 (fr) Biomarqueurs de la néphrotoxicité
WO2006052568A3 (fr) Inhibiteurs du tgf-beta
WO2008148790A8 (fr) Composés de cyclobutènedione substitués anti-inflammatoires
WO2011088027A8 (fr) Composés et procédés
WO2011081285A3 (fr) Polymère contenant un cycle aromatique pour une sous-couche de réserve, et composé de sous-couche de réserve comprenant le polymère
AU2007259257A8 (en) Antitumoral dihydropyran-2-one compounds
WO2011081945A3 (fr) Activation et activateurs de sirt6
WO2009042786A3 (fr) Carte de transaction carbone
WO2010026117A3 (fr) Dispositif d’alignement
WO2009000533A8 (fr) Nouveaux herbicides
WO2009076948A3 (fr) Réductones utilisées pour la production de biogaz
WO2009053980A3 (fr) Coupe-faim amélioré
WO2010117979A3 (fr) Inhibiteur de la recapture de la sérotonine-noradrénaline
WO2006078984A3 (fr) Utilisations de derives de methylphenidate
WO2009101199A3 (fr) Traitement de l'acné vulgaire, de la rosacée et du rhinophyme
WO2009158039A8 (fr) Procédés de photogravure comprenant des motifs amplifiés

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08848071

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08848071

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载